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Quantitative reverse transcription PCR (qRT-PCR) is the diagnostic standard for severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the causative agent of coronavirus disease 
(COVID-19) (1). Testing usually is conducted on 
upper respiratory specimens collected using swabs 
(1–3). However, this method requires multiple sam-
ples and has a low sensitivity (4). Swab sampling 
can cause patients to cough or sneeze, uncomfort-
able reactions that might also increase transmis-
sion risks to healthcare workers (A. Wyllie et al., 
unpub. data, https://doi.org/10.1101/2020.04.16.2
0067835). Sampling technique proficiency also var-
ies, especially during self-sampling (A. Wyllie et 
al., unpub. data, https://doi.org/10.1101/2020.0
4.16.20067835), which can result in false negatives. 
Furthermore, shortages of swabs, transport media, 
and personal protective equipment limit healthcare 
capacity to conduct SARS-CoV-2 tests that rely on 
swab sampling.
Saliva sampling is a noninvasive alternative to up-
per respiratory swabbing. We compared paired self-col-
lected saliva samples with healthcare worker–collected 
nasal and throat swab specimens from 110 patients with 
suspected SARS-CoV-2 infection. This analysis was 
part of a prospective study (Facilitating a SARS CoV-2 
Test for Rapid Triage) at the Royal Liverpool Univer-
sity and Aintree University Hospitals (Liverpool, UK). 
We recruited participants who had provided written 
informed consent and had COVID-19 symptoms. The 
National Health Service Research Ethics Committee 
(20/SC/0169) approved the study under Integrated Re-
search Application System no. 282147.
Within 24 hours after patient consent, we col-
lected nasal and throat swab specimens containing 1.0 
mL of Amies transport medium (COPAN Diagnos-
tics, https://www.copanusa.com). We also asked par-
ticipants to funnel their saliva into a sterile cryotube 
(SARSTEDT, https://www.sarstedt.com). We immedi-
ately extracted RNA from the swab samples; we stored 
saliva samples at –80°C until processing. We extracted 
viral RNA using the QIAamp Viral RNA Mini Kit (QIA-
GEN, https://www.qiagen.com) and tested 8 µL of ex-
tracted RNA using the genesig Real-Time Coronavirus 
COVID-19 PCR (genesig, https://www.genesig.com). 
We quantified viral loads using the manufacturer’s pos-
itive control (1.67 × 105 copies/µL) as reference.
Of the 110 adults recruited from April through June 
2020, a total of 61 (55.5%) were women. Most partici-
pants were hospitalized; 21 (19.1%) were discharged to 
home directly from the emergency department. Overall, 
12 (10.9%) saliva and 14 (12.7%) nasal and throat swab 
specimens of 110 paired samples tested positive for 
Figure. Viral load (copies/mL) of SARS-CoV-2 RNA recovered 
from paired saliva samples and nasal and throat swab specimens 
from 14 patients with coronavirus disease, United Kingdom, 2020. 
Viral loads are shown on a logarithmic scale. NS, not significant; 
NT, nasal and throat; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2.
PCR of upper respiratory specimens is the diagnostic 
standard for severe acute respiratory syndrome corona-
virus 2 infection. However, saliva sampling is an easy al-
ternative to nasal and throat swabbing. We found similar 
viral loads in saliva samples and in nasal and throat swab 
samples from 110 patients with coronavirus disease.
2770 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 11, November 2020
RESEARCH LETTERS
SARS-CoV-2 RNA. Viral loads for all samples ranged 
from 36 to 3.3 × 106 copies/mL. Overall viral loads were 
similar among all positive samples (Figure).
Insignificant viral load discrepancies existed 
among all positive samples (p = 0.1955 by Wilcoxon 
signed-rank paired test). Two patients tested positive 
(<10 copies/mL) on nasal and throat swab samples 
and negative on saliva samples; the discrepancies 
might have resulted from the different processing 
times of the 2 specimens because freeze-thawing can 
reduce the stability of RNA (5,6).
Saliva sampling can improve SARS-CoV-2 diag-
nostic techniques. Saliva samples are easier to collect 
than nasal and throat samples; the technique is nonin-
vasive, presumably preferred by the participant, and 
does not require sampling proficiency. In addition, 
saliva sampling does not require swabs and trans-
port media, which have limited availability during 
the pandemic. Our technique uses a funnel which, 
although helpful, might not be necessary for sample 
collection. Our study focused on symptomatic hospi-
talized participants; further research is needed on sa-
liva sampling for patients with mild and asymptom-
atic SARS-CoV-2 infection.
Further studies should document the effects of 
storage and transport on RNA and viral loads. Rapid 
processing of saliva samples might benefit patients in 
low- and middle-income countries, where the pandem-
ic is still accelerating and swab availability is limited 
(7). Furthermore, high-income countries can establish 
a cold chain for sample transportation. A cold chain 
could enable home sampling and screening of children 
who have rejected swabbing. It could also streamline 
research studies that require repeat sampling.
As rates of SARS-CoV-2 infection increase, we 
must continue to investigate efficient diagnostic strat-
egies. Easy and effective diagnostic techniques, such 
as saliva sampling, should be evaluated in certified 
clinical laboratories.
This article was preprinted at https://www.medrxiv.org/
content/10.1101/2020.07.09.20149534v1.
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